Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 3
2013 5
2014 4
2016 2
2017 2
2018 2
2019 2
2020 5
2021 16
2022 14
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.
Landi D, Bovis F, Grimaldi A, Annovazzi PO, Bertolotto A, Bianchi A, Borriello G, Brescia Morra V, Bucello S, Buscarinu MC, Caleri F, Capobianco M, Capra R, Cellerino M, Centonze D, Cerqua R, Chisari CG, Clerico M, Cocco E, Cola G, Cordioli C, Curti E, d'Ambrosio A, D'Amico E, De Luca G, Di Filippo M, Di Lemme S, Fantozzi R, Ferraro D, Ferraro E, Gallo A, Gasperini C, Granella F, Inglese M, Lanzillo R, Lorefice L, Lus G, Malucchi S, Margoni M, Mataluni G, Mirabella M, Moiola L, Nicoletti CG, Nociti V, Patti F, Pinardi F, Portaccio E, Pozzilli C, Ragonese P, Rasia S, Salemi G, Signoriello E, Vitetta F, Totaro R, Sormani MP, Amato MP, Marfia GA. Landi D, et al. Among authors: nicoletti cg. J Neurol Neurosurg Psychiatry. 2022 Sep 30:jnnp-2022-329657. doi: 10.1136/jnnp-2022-329657. Online ahead of print. J Neurol Neurosurg Psychiatry. 2022. PMID: 36180219
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
Schiavetti I, Inglese M, Frau J, Signoriello E, Caleri F, Stromillo ML, Ferrò MT, Rilla MT, Gandoglia I, Gazzola P, Brichetto G, Pasquali L, Grimaldi L, Ulivelli M, Marinelli F, Cordera S, Clerico M, Conte A, Salvetti M, Battaglia MA, Franciotta D, Uccelli A, Sormani MP; CovaXiMS Study Group. Schiavetti I, et al. Eur J Neurol. 2023 Aug;30(8):2357-2364. doi: 10.1111/ene.15830. Epub 2023 May 28. Eur J Neurol. 2023. PMID: 37154406
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
Bisecco A, Matrone F, Capobianco M, De Luca G, Filippi M, Granella F, Lus G, Marfia GA, Mirabella M, Patti F, Trojano M, Mascolo A, Copetti M, Tedeschi G, Gallo A; OCREVID study group on behalf of the Italian MS Register. Bisecco A, et al. J Neurol. 2024 Feb;271(2):699-710. doi: 10.1007/s00415-023-12084-4. Epub 2023 Nov 20. J Neurol. 2024. PMID: 37982852 Free PMC article.
Frailty and relapse activity in multiple sclerosis: A longitudinal observation.
Baione V, Canevelli M, Belvisi D, Buscarinu MC, Bellucci G, Fantozzi R, Nicoletti CG, Malatuni G, Cortese A, De Giglio L, Tartaglia M, Ferrazzano G, Malimpensa L, Leodori G, Bruno G, Ferraro E, Marfia GA, Centonze D, Salvetti M, Conte A. Baione V, et al. Among authors: nicoletti cg. Mult Scler Relat Disord. 2023 Apr;72:104603. doi: 10.1016/j.msard.2023.104603. Epub 2023 Mar 5. Mult Scler Relat Disord. 2023. PMID: 36905818
Interleukin-1β Alters Hebbian Synaptic Plasticity in Multiple Sclerosis.
Stampanoni Bassi M, Buttari F, Nicoletti CG, Mori F, Gilio L, Simonelli I, De Paolis N, Marfia GA, Furlan R, Finardi A, Centonze D, Iezzi E. Stampanoni Bassi M, et al. Among authors: nicoletti cg. Int J Mol Sci. 2020 Sep 23;21(19):6982. doi: 10.3390/ijms21196982. Int J Mol Sci. 2020. PMID: 32977401 Free PMC article. Clinical Trial.
What happens after fingolimod discontinuation? A multicentre real-life experience.
Landi D, Signori A, Cellerino M, Fenu G, Nicoletti CG, Ponzano M, Mancuso E, Fronza M, Ricchiuto ME, Boffa G, Inglese M, Marfia GA, Cocco E, Frau J. Landi D, et al. Among authors: nicoletti cg. J Neurol. 2022 Feb;269(2):796-804. doi: 10.1007/s00415-021-10658-8. Epub 2021 Jun 16. J Neurol. 2022. PMID: 34136943
COVID-19 vaccine hesitancy among Italian people with multiple sclerosis.
Proietti F, Landi D, Ponzano M, Cola G, Di Mauro G, Mataluni G, Nicoletti CG, Curcio G, Marfia GA. Proietti F, et al. Among authors: nicoletti cg. Neurol Sci. 2023 Mar;44(3):803-808. doi: 10.1007/s10072-022-06559-x. Epub 2022 Dec 26. Neurol Sci. 2023. PMID: 36567409 Free PMC article.
Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection.
Landi D, Cola G, Mantero V, Balgera R, Moiola L, Nozzolillo A, Dattola V, Sinisi L, Fantozzi R, Di Lemme S, Centonze D, Mataluni G, Nicoletti CG, Marfia GA. Landi D, et al. Among authors: nicoletti cg. Mult Scler Relat Disord. 2022 Jan;57:103345. doi: 10.1016/j.msard.2021.103345. Epub 2021 Oct 24. Mult Scler Relat Disord. 2022. PMID: 35158454 Free PMC article.
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context.
Sormani MP, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, Immovilli P, Capobianco M, De Rossi N, Brichetto G, Cocco E, Scandellari C, Cavalla P, Pesci I, Zito A, Confalonieri P, Marfia GA, Perini P, Inglese M, Trojano M, Brescia Morra V, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; MuSC-19 Study Group. Sormani MP, et al. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1):e1105. doi: 10.1212/NXI.0000000000001105. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34753829 Free PMC article.
45 results